Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
机构:[1]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.[2]Chongqing University Cancer Hospital & Chongqing Cancer Hospital, Chongqing, China.[3]Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China.[4]Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.华中科技大学同济医学院附属协和医院[5]The General Hospital of Chinese People's Liberation Army, Beijing, China.[6]The Affiliated Provincial Hospital of Anhui Medical University, Hefei, Anhui, China.[7]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.[8]The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.河北医科大学第四医院[9]Second Affiliated Hospital of Nanchang University, Nanchang, China.[10]Beijing Hospital, National Geriatric Medical Center, Beijing, China.[11]Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.浙江省肿瘤医院[12]Shanxi Cancer Hospital and the Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.[13]Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China.[14]Affiliated Hospital of Guizhou Medical University, Guizhou Cancer Hospital, Guiyang, Guizhou, China.[15]Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, Hunan, China.[16]Xijing Hospital of Fourth Military Medical University, Xi'an, China.[17]Tianjin Medical University Cancer Institute & Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin, China.[18]The Fifth Medical Center of PLA General Hospital, Beijing, China.[19]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.[20]Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.[21]Division of Biostatistics and Bioinformatics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.[22]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. medata@163.com.[23]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. yexiong12@163.com.
第一作者机构:[1]State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China.
推荐引用方式(GB/T 7714):
Yang Yong,Wang Ying,Liu Xin,et al.Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.[J].Leukemia.2021,35(9):2736-2737.doi:10.1038/s41375-021-01371-6.
APA:
Yang Yong,Wang Ying,Liu Xin,He Xia,Zhang Li-Ling...&Li Ye-Xiong.(2021).Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study..Leukemia,35,(9)
MLA:
Yang Yong,et al."Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.".Leukemia 35..9(2021):2736-2737